iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Application for the OTC-HOPE Phase 1/2 Study of ECUR-506

ECUR-506 is a gene editing-based investigational therapy for the treatment of Ornithine Transcarbamylase (OTC) deficiency

Related Keywords

New York ,United States ,Australia ,Australian ,Jamesm Wilson ,Roseh Weiss ,Joe Truitt ,George Diaz ,David Garrett ,Janine Bogris ,University Of Pennsylvania Gene Therapy Program ,Company Clinical Trial Notification ,University Of Pennsylvania Penn ,University Of Pennsylvania ,Gene Therapy Program ,Linkedin ,Secure Inc ,Precision Biosciences Inc ,Australian Therapeutic Goods Administration ,Perelman School Of Medicine ,Nasdaq ,Disease Center ,Ornithine Transcarbamylase ,Clinical Trial Notification ,Chief Executive Officer ,Vice President ,Therapeutic Area Lead ,Urea Cycle Disorders ,Mount Sinai Hospital ,Orphan Disease Center ,Perelman School ,Precision Biosciences ,Chief Scientific Advisor ,Press Release , ,